Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery-Reference-Cited by-同舟云学术

Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery

Published:2020-06-07 Issue:10 Volume:22 Page:1422-1424
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Grossman Stuart A¹^ORCID,Romo Carlos G¹,Rudek Michelle A¹,Supko Jeffrey²,Fisher Joy¹,Nabors L Burt³,Wen Patrick Y⁴,Peereboom David M⁵,Ellingson Benjamin M⁶,Elmquist William⁷,Barker Fred G²,Kamson David¹,Sarkaria Jann N⁸,Timmer William⁹,Bindra Ranjit S¹⁰,Ye Xiaobu¹

Affiliation:

1. Johns Hopkins University, Baltimore, Maryland

2. Massachusetts General Hospital, Boston, Massachusetts

3. University of Alabama Birmingham, Birmingham, Alabama

4. Dana-Farber Cancer Institute, Boston, Massachusetts

5. Cleveland Clinic, Cleveland, Ohio

6. University of California Los Angeles, Los Angeles, California

7. University of Minnesota, Minneapolis, Minnesota

8. Mayo Clinic, Rochester, Minnesota

9. National Cancer Institute, Bethesda, Maryland

10. Yale University, New Haven, Connecticut

Funder